Cellectar BioSciences Inc. has announced a one-for-thirty reverse stock split of its common stock, effective June 24, 2025. This move was executed by amending its Second Amended and Restated Certificate of Incorporation. Instead of issuing fractional shares, the aggregate will be sold by the transfer agent, and proceeds will be distributed to shareholders.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.